Antibody neutralization and escape by HIV-1

Area of Science:

• Immunology
• Virology
• Structural Biology

Background:

• Neutralizing antibodies (Nab) are critical for pathogen defense, but their precise role in human immunodeficiency virus type 1 (HIV-1) infection remains incompletely understood.
• Understanding HIV-1 neutralization escape mechanisms is crucial for developing effective vaccines and therapies.

Purpose of the Study:

• To investigate the role and dynamics of autologous neutralizing antibodies (Nab) during acute HIV-1 infection.
• To elucidate the mechanisms by which HIV-1 develops resistance to neutralizing antibodies.

Main Methods:

• Analysis of plasma samples from patients during acute HIV-1 infection.
• Detection and characterization of autologous Nab and their viral inhibitory activity.
• Genomic sequencing of the HIV-1 env gene to identify mutations associated with antibody escape.
• Functional assays involving mutational substitution to validate proposed escape mechanisms.

Main Results:

• Autologous Nab were detected as early as 52 days post-HIV-1 specific antibody detection.
• Nab activity led to the replacement of neutralization-sensitive virus with resistant strains.
• HIV-1 escape involved sparse mutations primarily in N-linked glycosylation sites of the env gene, forming a 'glycan shield'.
• This 'glycan shield' mechanism allows virus to evade antibody binding while maintaining receptor binding.

Conclusions:

• An evolving 'glycan shield' is a novel mechanism of neutralization escape in HIV-1.
• This mechanism contributes significantly to HIV-1 persistence despite the host's evolving antibody response.
• Targeting or overcoming this glycosylation-dependent escape strategy may be key for therapeutic interventions.